- Home
- PGNY vs VCEL Comparison
PGNY vs VCEL Comparison
Compare PGNY & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PGNY | VCEL |
|---|---|---|
| Price | $25.48 | $35.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $26.50 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 1.7M | 593.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.04 | ★ 60.00 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $1,288,661,000.00 | $276,259,000.00 |
| Revenue This Year | $8.87 | $19.40 |
| Revenue Next Year | $9.76 | $18.24 |
| P/E Ratio | $86.17 | ★ N/A |
| Revenue Growth | 10.40 | ★ 16.45 |
| 52 Week Low | $16.10 | $28.95 |
| 52 Week High | $28.75 | $45.97 |
Technical Indicators
Market Signals| Indicator | PGNY | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 67.70 | 57.76 |
| Support Level | $25.14 | $35.85 |
| Resistance Level | $27.51 | $38.31 |
| Average True Range (ATR) | 0.93 | 1.56 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 85.75 | 80.21 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.